207 related articles for article (PubMed ID: 37870091)
1. Systematic characterization of antibody-drug conjugate targets in central nervous system tumors.
Coy S; Lee JS; Chan SJ; Woo T; Jones J; Alexandrescu S; Wen PY; Sorger PK; Ligon KL; Santagata S
Neuro Oncol; 2024 Mar; 26(3):458-472. PubMed ID: 37870091
[TBL] [Abstract][Full Text] [Related]
2. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
Ferraro E; Drago JZ; Modi S
Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
[TBL] [Abstract][Full Text] [Related]
3. Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2.
Schlam I; Moges R; Morganti S; Tolaney SM; Tarantino P
Crit Rev Oncol Hematol; 2023 Oct; 190():104090. PubMed ID: 37562695
[TBL] [Abstract][Full Text] [Related]
4. B7-H3 in Brain Malignancies: Immunology and Immunotherapy.
Guo X; Chang M; Wang Y; Xing B; Ma W
Int J Biol Sci; 2023; 19(12):3762-3780. PubMed ID: 37564196
[TBL] [Abstract][Full Text] [Related]
5. Antibody-drug conjugates in solid tumors: a look into novel targets.
Criscitiello C; Morganti S; Curigliano G
J Hematol Oncol; 2021 Jan; 14(1):20. PubMed ID: 33509252
[TBL] [Abstract][Full Text] [Related]
6. Antibody-Drug Conjugates for Lung Cancer: Payloads and Progress.
Rosner S; Valdivia A; Hoe HJ; Murray JC; Levy B; Felip E; Solomon BJ
Am Soc Clin Oncol Educ Book; 2023 May; 43():e389968. PubMed ID: 37163707
[TBL] [Abstract][Full Text] [Related]
7. Leveraging TROP2 Antibody-Drug Conjugates in Solid Tumors.
Nelson BE; Meric-Bernstam F
Annu Rev Med; 2024 Jan; 75():31-48. PubMed ID: 37758237
[TBL] [Abstract][Full Text] [Related]
8. 'Targeting' Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer-An Updated Review.
Verma S; Breadner D; Raphael J
Curr Oncol; 2023 Apr; 30(4):4329-4350. PubMed ID: 37185443
[TBL] [Abstract][Full Text] [Related]
9. Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response.
Bosi C; Bartha Á; Galbardi B; Notini G; Naldini MM; Licata L; Viale G; Mariani M; Pistilli B; Ali HR; André F; Piras M; Callari M; Barreca M; Locatelli A; Viganò L; Criscitiello C; Pusztai L; Curigliano G; Győrffy B; Dugo M; Bianchini G
Eur J Cancer; 2023 Dec; 195():113379. PubMed ID: 37913680
[TBL] [Abstract][Full Text] [Related]
10. Antibody-Drug Conjugates in Prostate Cancer: A Systematic Review.
Sardinha M; Palma Dos Reis AF; Barreira JV; Fontes Sousa M; Pacey S; Luz R
Cureus; 2023 Feb; 15(2):e34490. PubMed ID: 36874351
[TBL] [Abstract][Full Text] [Related]
11. ITC-6102RO, a novel B7-H3 antibody-drug conjugate, exhibits potent therapeutic effects against B7-H3 expressing solid tumors.
Shin SH; Ju EJ; Park J; Ko EJ; Kwon MR; Lee HW; Son GW; Park YY; Kim YJ; Song SY; Lee S; Seo BS; Song JA; Lim S; Jung D; Kim S; Lee H; Park SS; Jeong SY; Choi EK
Cancer Cell Int; 2023 Aug; 23(1):172. PubMed ID: 37596639
[TBL] [Abstract][Full Text] [Related]
12. Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers.
Yu J; Fang T; Yun C; Liu X; Cai X
Front Mol Biosci; 2022; 9():847835. PubMed ID: 35295841
[TBL] [Abstract][Full Text] [Related]
13. Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments.
Loganzo F; Tan X; Sung M; Jin G; Myers JS; Melamud E; Wang F; Diesl V; Follettie MT; Musto S; Lam MH; Hu W; Charati MB; Khandke K; Kim KS; Cinque M; Lucas J; Graziani E; Maderna A; O'Donnell CJ; Arndt KT; Gerber HP
Mol Cancer Ther; 2015 Apr; 14(4):952-63. PubMed ID: 25646013
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab Deruxtecan, Antibody-Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing Consortium.
Hingorani P; Zhang W; Zhang Z; Xu Z; Wang WL; Roth ME; Wang Y; Gill JB; Harrison DJ; Teicher BA; Erickson SW; Gatto G; Kolb EA; Smith MA; Kurmasheva RT; Houghton PJ; Gorlick R
Mol Cancer Ther; 2022 Aug; 21(8):1318-1325. PubMed ID: 35657346
[TBL] [Abstract][Full Text] [Related]
15. Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload.
Kondrashov A; Sapkota S; Sharma A; Riano I; Kurzrock R; Adashek JJ
Pharmaceutics; 2023 Aug; 15(8):. PubMed ID: 37631374
[TBL] [Abstract][Full Text] [Related]
16. Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs.
Andreev J; Thambi N; Perez Bay AE; Delfino F; Martin J; Kelly MP; Kirshner JR; Rafique A; Kunz A; Nittoli T; MacDonald D; Daly C; Olson W; Thurston G
Mol Cancer Ther; 2017 Apr; 16(4):681-693. PubMed ID: 28108597
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates.
Jackson D; Atkinson J; Guevara CI; Zhang C; Kery V; Moon SJ; Virata C; Yang P; Lowe C; Pinkstaff J; Cho H; Knudsen N; Manibusan A; Tian F; Sun Y; Lu Y; Sellers A; Jia XC; Joseph I; Anand B; Morrison K; Pereira DS; Stover D
PLoS One; 2014; 9(1):e83865. PubMed ID: 24454709
[TBL] [Abstract][Full Text] [Related]
18. PF-06804103, A Site-specific Anti-HER2 Antibody-Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers.
Graziani EI; Sung M; Ma D; Narayanan B; Marquette K; Puthenveetil S; Tumey LN; Bikker J; Casavant J; Bennett EM; Charati MB; Golas J; Hosselet C; Rohde CM; Hu G; Guffroy M; Falahatpisheh H; Finkelstein M; Clark T; Barletta F; Tchistiakova L; Lucas J; Rosfjord E; Loganzo F; O'Donnell CJ; Gerber HP; Sapra P
Mol Cancer Ther; 2020 Oct; 19(10):2068-2078. PubMed ID: 32747418
[TBL] [Abstract][Full Text] [Related]
19. SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models.
Gray E; Ulrich M; Epp A; Younan P; Sahetya D; Hensley K; Allred S; Huang LY; Hahn J; Gahnberg K; Treuting PM; Trueblood ES; Gosink JJ; Thurman R; Wo S; Spahr K; Haass EJ; Snead K; Miller D; Padilla M; Smith AJ; Frantz C; Schrum JP; Nazarenko N; Gardai SJ
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37793853
[TBL] [Abstract][Full Text] [Related]
20. HER2-/HER3-Targeting Antibody-Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors.
Yonesaka K
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33801379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]